Prolactinomas in males: any differences?

Hadar Duskin-Bitan, Ilan Shimon

Research output: Contribution to journalReview articlepeer-review

Abstract

Context: Prolactinomas in men are usually large and invasive, presenting with signs and symptoms of hypogonadism and mass effects, including visual damage. Prolactin levels are high, associated with low testosterone, anemia, metabolic syndrome and if long-standing also osteoporosis. Results: Medical treatment with the dopamine agonist, cabergoline, became the preferred first-line treatment for male prolactinomas as well as for giant tumors, leading to prolactin normalization in ~ 80% of treated men, and tumor shrinkage, improved visual fields and recovery of hypogonadism in most patients. Multi-modal approach including surgery and occasionally radiotherapy together with a high-dose cabergoline is saved for resistant and invasive adenomas. Experimental treatments including temozolomide or pasireotide may improve clinical response in men harboring resistant prolactinomas. Conclusions: Compared to other pituitary adenomas, secreting and non-secreting, where pituitary surgery is the recommended first-line treatment, men with prolactinomas will usually respond to medical treatment with no need for any additional treatment.

Original languageEnglish
Pages (from-to)52-57
Number of pages6
JournalPituitary
Volume23
Issue number1
DOIs
StatePublished - 1 Feb 2020

Keywords

  • Cabergoline
  • Dopamine agonist
  • Men
  • Prolactin
  • Prolactinoma

Fingerprint

Dive into the research topics of 'Prolactinomas in males: any differences?'. Together they form a unique fingerprint.

Cite this